{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T19:47:08Z","timestamp":1790192828695,"version":"4.1.0"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,6,19]],"date-time":"2024-06-19T00:00:00Z","timestamp":1718755200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,6,19]],"date-time":"2024-06-19T00:00:00Z","timestamp":1718755200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100017590","name":"Universit\u00e4tsklinikum Essen","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100017590","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Nephrol"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>The complement factor 5 (C5)-inhibitor eculizumab has been established as standard-of-care for the treatment of atypical hemolytic uremic syndrome (aHUS). In 2021, the long-acting C5-inhibitor ravulizumab was approved, extending intervals of intravenous treatment from two to eight weeks resulting in improvement of quality of life for patients and lowering direct and indirect therapy associated costs.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>This multicenter, retrospective data analysis of 32 adult patients with aHUS (including 10 kidney transplant recipients) treated with eculizumab for at least three months and switched to ravulizumab aims to evaluate the safety and efficacy of switching medication in the real-world setting. Hematologic parameters, kidney function, concurrent therapy and aHUS associated events were evaluated three months before and until up to 12 months after switching to ravulizumab.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Mean age (range) at ravulizumab initiation was 41 years (19\u201378 years) and 59% of the patients were female. Genetic analysis was available for all patients with 72% showing a pathogenic variant. Median time (range) on eculizumab before switching was 20 months (3\u2013120 months). No new events of TMA or worsening of renal function were reported during up to 12 months of follow-up during ravulizumab treatment.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>This is the largest, non-industry derived, multi-center retrospective analysis of adult patients with aHUS switching C5-inhibitor treatment from eculizumab to ravulizumab in the real-world setting. Switching to ravulizumab was safe and efficient resulting in sustained hematological stability and preservation of renal function.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12882-024-03638-3","type":"journal-article","created":{"date-parts":[[2024,6,19]],"date-time":"2024-06-19T16:05:00Z","timestamp":1718813100000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":20,"title":["Clinical efficacy and safety of switching from eculizumab to ravulizumab in adult patients with aHUS\u2013 real-world data"],"prefix":"10.1186","volume":"25","author":[{"given":"Kristina","family":"Sch\u00f6nfelder","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucas","family":"K\u00fchne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lena","family":"Schulte-Kemna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica","family":"Kaufeld","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hana","family":"Rohn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Kribben","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bernd","family":"Schr\u00f6ppel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul T.","family":"Brinkk\u00f6tter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anja","family":"G\u00e4ckler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,6,19]]},"reference":[{"issue":"11","key":"3638_CR1","first-page":"2","volume":"14 Suppl 11","author":"J Laurence","year":"2016","unstructured":"Laurence J, Haller HM, Mannucci PM, Nangaku M, Praga M. Rodriguez de C\u00f3rdoba S: Atypical hemolytic uremic syndrome (aHUS): essential aspects of an acute diagnosis. Clin Adv Hematol Oncol. 2016;14 Suppl 11(11):2\u201315.","journal-title":"Clin Adv Hematol Oncol"},{"issue":"4","key":"3638_CR2","doi-asserted-by":"publisher","first-page":"554","DOI":"10.2215\/CJN.04760512","volume":"8","author":"V Fremeaux-Bacchi","year":"2013","unstructured":"Fremeaux-Bacchi V, Fakhouri F, Garnier A, Bienaim\u00e9 F, Dragon-Durey M, Ngo S, Moulin B, Servais A, Provot F, Rostaing L, et al. Genetics and outcome of atypical hemolytic uremic syndrome: a nationwide French series comparing children and adults. Clin J Am Soc Nephrol. 2013;8(4):554\u201362.","journal-title":"Clin J Am Soc Nephrol"},{"issue":"3","key":"3638_CR3","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1111\/ajt.12077","volume":"13","author":"M Le Quintrec","year":"2013","unstructured":"Le Quintrec M, Zuber J, Moulin B, Kamar N, Jablonski M, Lionet A, Chatelet V, Mousson C, Mourad G, Bridoux F, et al. Complement genes strongly predicht recurrence and graft outcome in adult renal transplant recipients with atypical hemolytic and uremic syndrome. Am J Transplant. 2013;13(3):663\u201375.","journal-title":"Am J Transplant"},{"issue":"1","key":"3638_CR4","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1053\/j.ajkd.2015.12.034","volume":"68","author":"F Fakhouri","year":"2016","unstructured":"Fakhouri F, Hourmant M, Campistol J, Cataland S, Espinosa M, Gaber A, Menne J, Minetti E, Provot F, Rondeau E, et al. Terminal complement inhibitor eculizumab in adult patients with atypical hemolytic uremic syndrome: a single-arm, open-label trial. Am J Kidney Dis. 2016;68(1):84\u201393.","journal-title":"Am J Kidney Dis"},{"issue":"12","key":"3638_CR5","doi-asserted-by":"publisher","first-page":"2449","DOI":"10.1681\/ASN.2019040331","volume":"30","author":"J Zuber","year":"2019","unstructured":"Zuber J, Frimat M, Caillard S, Kamar N, Gatault P, Petiprez F, Couzi L, Jourde-Chiche N, Chatelet V, Gaisne R, et al. Use of higly individualized complement blockade has revolutionized clinical outcomes after kidney transplantation and renal epidemiology of atypical hemolytic uremic syndrome. J Am Soc Nephrol. 2019;30(12):2449\u201363.","journal-title":"J Am Soc Nephrol"},{"issue":"4","key":"3638_CR6","doi-asserted-by":"publisher","first-page":"e0195909","DOI":"10.1371\/journal.pone.0195909","volume":"13","author":"D Sheridan","year":"2018","unstructured":"Sheridan D, Yu Z, Zhang Y, Patel R, Sun F, Lasaro M, Bouchard K, Andrien B, Marozsan A, Wang Y, et al. Design and preclinical characterization of ALXN1210: a novel anti-C5 antibody with extended duration of action. PLoS One. 2018;13(4):e0195909.","journal-title":"PLoS One"},{"issue":"7","key":"3638_CR7","doi-asserted-by":"publisher","first-page":"1105","DOI":"10.1080\/19420862.2017.1359455","volume":"9","author":"D Yang","year":"2017","unstructured":"Yang D, Giragossian C, Castellano S, Lasaro M, Xiao H, Saraf H, Hess Kenny C, Rybina I, Huang Z, Ahlberg J, et al. Maximizing in vivo target clearance by design of pH-dependent target binding antibodies with altered affinity to FcRn. MAbs. 2017;9(7):1105\u201317.","journal-title":"MAbs"},{"issue":"6","key":"3638_CR8","doi-asserted-by":"publisher","first-page":"1287","DOI":"10.1016\/j.kint.2020.01.035","volume":"97","author":"E Rondeau","year":"2020","unstructured":"Rondeau E, Scully M, Ariceta G, Barbour T, Cataland S, Heyne N, Miyakawa Y, Ortiz S, Swenson E, Vallee M, et al. The long-acting C5 inhibitor, ravulizumab, is effective and safe in adult patients with atypical hemolytic uremic syndrome naive to complement inhibitor treatment. Kidney Int. 2020;97(6):1287\u201396.","journal-title":"Kidney Int"},{"issue":"6","key":"3638_CR9","doi-asserted-by":"publisher","first-page":"1603","DOI":"10.1016\/j.ekir.2021.03.884","volume":"6","author":"T Barbour","year":"2021","unstructured":"Barbour T, Scully M, Ariceta G, Cataland S, Garlo K, Heyne N, Luque Y, Menne J, Miyakawa Y, Yoon S, et al. Long-term efficacy and safety of the long-acting complement C5 inhibitor ravulizumab for the treatment of atypical hemolytic uremic syndrome in adults. Kidney Int Rep. 2021;6(6):1603\u201313.","journal-title":"Kidney Int Rep"},{"issue":"5","key":"3638_CR10","doi-asserted-by":"publisher","first-page":"261","DOI":"10.5414\/CN110516","volume":"97","author":"I Tomazos","year":"2022","unstructured":"Tomazos I, Hatswell A, Cataland S, Chen P, Freemantle N, Lommele A, Deighton K, Knowles E, Sheerin N, Rondeau E. Comparative efficacy of ravulizumab and eculizumab in the treatment of atypical hemolytic uremic syndrome: an indirect comparison using clincal trial data. Clin Nephrol. 2022;97(5):261\u201372.","journal-title":"Clin Nephrol"},{"issue":"6","key":"3638_CR11","doi-asserted-by":"publisher","first-page":"3129","DOI":"10.1007\/s00415-023-11617-1","volume":"270","author":"T Vu","year":"2023","unstructured":"Vu T, Ortiz S, Katsuno M, Annane D, Mantegazza R, Beasley K, Aguzzi R, Howard J Jr. Ravulizumab pharmacokinetics and pharmacodynamics in patients with generalized myasthenia gravis. J Neurol. 2023;270(6):3129\u201337.","journal-title":"J Neurol"},{"issue":"12","key":"3638_CR12","doi-asserted-by":"publisher","first-page":"976","DOI":"10.1016\/S1474-4422(17)30369-1","volume":"16","author":"J Howard Jr","year":"2017","unstructured":"Howard J Jr, Utsugisawa K, Benatar M, Murai H, Barohn R, Illa I, Jacob S, Vissing J, Burns T, Kissel J, et al. Safety and efficacy of eculizumab in anti-acetylcholine receptor antibody-positive refractory generalised myasthenia gravis (REGAIN): a phase 3, randomised, double-blind, placebo-controlled, multicentre study. Lancet Neurol. 2017;16(12):976\u201386.","journal-title":"Lancet Neurol"},{"key":"3638_CR13","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2021.696385","volume":"12","author":"J Monteleone","year":"2021","unstructured":"Monteleone J, Gao X, Kleijn H, Bellanti F, Pelto R. Eculizumab pharmacokinetics and pharmacodynamics in patients with generalized myasthenia gravis. Front Neurol. 2021;12: 696385.","journal-title":"Front Neurol"},{"key":"3638_CR14","unstructured":"Ultomiris prescribing information.\u00a0https:\/\/ec.europa.eu\/health\/documents\/community-register\/2020\/20200625148516\/anx_148516_de.pdf. Accessed 1 Jan 2024."},{"issue":"10","key":"3638_CR15","doi-asserted-by":"publisher","first-page":"1844","DOI":"10.2215\/CJN.02210310","volume":"5","author":"M Noris","year":"2010","unstructured":"Noris M, Caprioli J, Bresin E, Mossali C, Pianetti G, Gamba S, Daina E, Fenili C, Castelletti F, Sorosina A, et al. Relative role of genetic complement abnormalities in sporadic and familial aHUS and their impact on clinical phenotype. Clin J Am Soc Nephrol. 2010;5(10):1844\u201359.","journal-title":"Clin J Am Soc Nephrol"},{"issue":"2","key":"3638_CR16","doi-asserted-by":"publisher","first-page":"408","DOI":"10.1016\/j.kint.2018.02.029","volume":"94","author":"F Schaefer","year":"2018","unstructured":"Schaefer F, Ardissino G, Ariceta G, Fakhouri F, Scully M, Isbel N, Lommel\u00e9 A, Kupelian V, Gasteyger C, Greenbaum L, et al. Clinical and genetic predictors of atypical hemolytic uremic syndrome phenotype and outcome. Kidney Int. 2018;94(2):408\u201318.","journal-title":"Kidney Int"},{"issue":"8","key":"3638_CR17","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1038\/s41581-021-00424-4","volume":"17","author":"F Fakhouri","year":"2021","unstructured":"Fakhouri F, Fr\u00e9meaux-Bacchi V. Thrombotic microangiopathy in aHUS and beyond: clinical clues from complement genetics. Nat Rev Nephrol. 2021;17(8):543\u201353.","journal-title":"Nat Rev Nephrol"},{"issue":"18","key":"3638_CR18","doi-asserted-by":"publisher","first-page":"2438","DOI":"10.1182\/blood.2020009280","volume":"137","author":"F Fakhouri","year":"2021","unstructured":"Fakhouri F, Fila M, Hummel A, Ribes D, Sellier-Leclerc A, Ville S, Pouteil-Noble C, Coindre J, Le Quintrec M, Rondeau E, et al. Eculizumab discontinuation in children and adults with atypical haemolytic uremic syndrome: a prospective multicentric study. Blood. 2021;137(18):2438\u201349.","journal-title":"Blood"},{"issue":"2","key":"3638_CR19","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1159\/000492033","volume":"48","author":"S Olson","year":"2018","unstructured":"Olson S, Lu E, Sulpizio E, Shatzel J, Rueda J, DeLoughery T. When to stop eculizumab in complement-mediated thrombotic microangiopathies. Am J Nephrol. 2018;48(2):96\u2013107.","journal-title":"Am J Nephrol"},{"issue":"4","key":"3638_CR20","first-page":"221","volume":"18","author":"J Laurence","year":"2020","unstructured":"Laurence J. Defining treatment duratin in atypical hemolytic uremic syndrome in adults: a clinical and pathological approach. Clin Adv Hematol Oncol. 2020;18(4):221\u201330.","journal-title":"Clin Adv Hematol Oncol"},{"issue":"1","key":"3638_CR21","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1186\/s12882-019-1314-1","volume":"20","author":"J Menne","year":"2019","unstructured":"Menne J, Delmas Y, Fakhouri F, Licht C, Lommel\u00e9 A, Minetti E, Provot F, Rondeau E, Sheerin N, Wang J, et al. Outcomes in patients with atypical hemolytic uremic syndrome treated with eculizumab in a long-term observational study. BMC Nephrol. 2019;20(1):125.","journal-title":"BMC Nephrol"},{"key":"3638_CR22","doi-asserted-by":"publisher","first-page":"1264310","DOI":"10.3389\/fmed.2023.1264310","volume":"10","author":"A Avila","year":"2023","unstructured":"Avila A, Cao M, Espinosa M, Manrique J, Morales E. Recommendations for the individualised management of atypical hemolytic uremic syndrome in adults. Front Med. 2023;10:1264310.","journal-title":"Front Med"},{"issue":"4","key":"3638_CR23","doi-asserted-by":"publisher","first-page":"889","DOI":"10.1007\/s00467-020-04774-2","volume":"36","author":"K Tanaka","year":"2021","unstructured":"Tanaka K, Adams B, Aris A, Fujita N, Ogawa M, Ortiz S, Vallee M, Greenbaum L. The long-acting C5 inhibitor, ravulizumab, is efficacious and safe in pediatric patients with atypical hemolytic uremic syndrome previously treated with eculizumab. Pediatr Nephrol. 2021;36(4):889\u201398.","journal-title":"Pediatr Nephrol"},{"issue":"5","key":"3638_CR24","doi-asserted-by":"publisher","first-page":"775","DOI":"10.1007\/s00467-014-2990-5","volume":"30","author":"W Hayes","year":"2015","unstructured":"Hayes W, Tschumi S, Ling S, Feber J, Kirschfink M. LIcht C: Eculizumab hepatotoxicity in pediatric aHUS. Pediatr Nephrol. 2015;30(5):775\u201381.","journal-title":"Pediatr Nephrol"},{"issue":"4","key":"3638_CR25","doi-asserted-by":"publisher","first-page":"448","DOI":"10.1016\/j.nefroe.2018.04.004","volume":"38","author":"A Oruc","year":"2018","unstructured":"Oruc A, Ayar Y, Vuruskan B, Yildiz A, Aktas N, Yavuz M, Gullulu M, Dilek K, Ersoy A. Hepatotoxicity associated with eculizumab in a patient with atypical hemolytic uremic syndrome. Nefrologia (Engl Ed). 2018;38(4):448\u201350.","journal-title":"Nefrologia (Engl Ed)"},{"key":"3638_CR26","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/00207454.2023.2253361","volume":"31","author":"K Rabia","year":"2023","unstructured":"Rabia K, Faruk T, Furkan S, Lazrak E, Ozen P, Tuncer A. Probable eculizumab-associanted hepatotoxicity in a patient with neuromyelitis optica: a case report. Int J Neurosci. 2023;31:1\u20135.","journal-title":"Int J Neurosci"},{"issue":"4","key":"3638_CR27","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1097\/QCO.0000000000000279","volume":"29","author":"E Benamu","year":"2016","unstructured":"Benamu E, Montoya J. Infections associated with the use of eculizumab: recommendations for prevention and prophylaxis. Curr Opin Infect Dis. 2016;29(4):319\u201329.","journal-title":"Curr Opin Infect Dis"},{"issue":"2","key":"3638_CR28","first-page":"298","volume":"35","author":"A G\u00e4ckler","year":"2018","unstructured":"G\u00e4ckler A, Kaulfu\u00df M, Rohn H, Vogel U, Claus H, Feldkamp T, Kribben A, Witzke O. Failure of first menigococcal vaccination in patients with atypical haemolytic uraemic syndrome treated with eculizumab. Nephrol Dial Transplant. 2018;35(2):298\u2013303.","journal-title":"Nephrol Dial Transplant."},{"issue":"Suppl. 1","key":"3638_CR29","first-page":"490","volume":"30","author":"S Fam","year":"2023","unstructured":"Fam S, Werneburg B, Pandya S, Parks B, Mashhoon Y, Allen K, Frick G, Beasley K, Zodiatis A, Chitikireddi V, et al. Clinical and real-world pharmacovigilance data of meningococcal infections in eculizumab- or ravulizumab-treated patients (EPO-260). Eur J Neurol. 2023;30(Suppl. 1):490.","journal-title":"Eur J Neurol"},{"key":"3638_CR30","doi-asserted-by":"publisher","DOI":"10.1016\/j.jim.2020.112944","volume":"490","author":"M Willrich","year":"2021","unstructured":"Willrich M, Ladwig P, Martinez M, Sridharan M, Go R, Murray D. Monitoring ravulizumab effect on complement assays. J Immunol Methods. 2021;490: 112944.","journal-title":"J Immunol Methods"},{"issue":"Supplement 1","key":"3638_CR31","doi-asserted-by":"publisher","first-page":"1099","DOI":"10.1182\/blood-2019-122421","volume":"134","author":"S Cataland","year":"2019","unstructured":"Cataland S, Ariceta G, Chen P, Dixon B. garlo K, Greenbaum L, Rondeau E, Scully M, Ortiz S: Discordance between free C5 and CH50 complement assays in measuring complement C5 inhibition in patients with aHUS treated with ravulizumab. Blood. 2019;134(Supplement 1):1099.","journal-title":"Blood"},{"key":"3638_CR32","doi-asserted-by":"publisher","first-page":"10846","DOI":"10.3389\/ti.2022.10846","volume":"35","author":"U Jehn","year":"2022","unstructured":"Jehn U, Altuner U, Pavenst\u00e4dt H, Reuter S. First report on successful conversion of long-term treatment of recurrent atypical hemolytic uremic syndrome with eculizumab to ravulizumab in a renal transplant patient. Transplant Int. 2022;35:10846.","journal-title":"Transplant Int"},{"key":"3638_CR33","doi-asserted-by":"publisher","first-page":"987","DOI":"10.1681\/ASN.20233411S1987a","volume":"34","author":"F Schaefer","year":"2023","unstructured":"Schaefer F, Al-Dakkak I, Anokhina E, Cohen D, Greenbaum L, Ariceta M. Chracteristics and outcome of patients with atypical hemolytic uremic syndrome switching to ravulizumab from eculizumab: a global registry analysis. J Am Soc Nephrol. 2023;34:987.","journal-title":"J Am Soc Nephrol."},{"issue":"8","key":"3638_CR34","doi-asserted-by":"publisher","first-page":"2307","DOI":"10.1016\/S0149-2918(03)80222-9","volume":"25","author":"A Richter","year":"2003","unstructured":"Richter A, Anton S, Koch P, Dennett S. The impact of reducing dose frequency on health outcomes. Clin Ther. 2003;25(8):2307\u201335.","journal-title":"Clin Ther"},{"issue":"1","key":"3638_CR35","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1002\/jha2.632","volume":"4","author":"J Jang","year":"2022","unstructured":"Jang J, Gomez R, Bumbea H, Nogaieva L, Wong L, Lim S, Kim Y, Park J. A phase III, radomised, double-blind, multi-national clinical trial comparing SB12 (proposed eculizumab biosimilar) and reference eculizumab in patients with paroxysmal nocturnal haemoglobinuria. EJHaem. 2022;4(1):26\u201336.","journal-title":"EJHaem"},{"issue":"1","key":"3638_CR36","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1080\/13696998.2022.2027706","volume":"25","author":"A Levy","year":"2022","unstructured":"Levy A, Chen P, Johnston K, Wang Y, Popoff E, Tomazos I. Quantifying the economic effects of ravulizumab versus eculizumab treatment in patients with atypical hemolytic uremic syndrome. J Med Econ. 2022;25(1):249\u201359.","journal-title":"J Med Econ"}],"container-title":["BMC Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12882-024-03638-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12882-024-03638-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12882-024-03638-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,19]],"date-time":"2024-06-19T16:05:47Z","timestamp":1718813147000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcnephrol.biomedcentral.com\/articles\/10.1186\/s12882-024-03638-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6,19]]},"references-count":36,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["3638"],"URL":"https:\/\/doi.org\/10.1186\/s12882-024-03638-3","relation":{},"ISSN":["1471-2369"],"issn-type":[{"value":"1471-2369","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,6,19]]},"assertion":[{"value":"13 January 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 June 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 June 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was conducted in compliance with Good Clinical Practice and the Declaration of Helsinki, and in accordance with applicable legal and regulatory requirements. The study was approved by the Ethic Committee of the University of Duisburg-Essen (23\u201311248-BO) as well as by the Ethic Committees of the Medical School Hannover, and the Universities of Cologne and Ulm. Due to the retrospective character of the study need to consent was waived.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"K.S. and H.R. declare no competing interests. L.K. has received consulting fees from Alexion and research funding from Sanofi-Genzyme. L.S.K. reports consultant honoraria and travel grants from Alexion. J.K. reports speaker honoraria and participation in advisory boards from Alexion, Sanofi, and Chiesi. A.K. has received grants for clinical studies, speaker fees, honoraria and travel expenses from Actelion, Amgen, Amicus, Alexion, Astellas, Bayer, Baxter, Binding Site, Bristol-Myers Squibb, Chiesi, CytoSorbents, Fresenius, GlaxoSmithKline, Hexal, Janssen, Kyowa Kirin, MSD, Novartis, Otsuka, Peripal, Pfizer, Roche, Sanofi, Shire, Teva and Vifor Fresenius Medical. B.S. has received consultant\/speaker honoraria from Alexion, Amgen, Novartis, Astellas, Bristol Myers Squibb, Boehringer Ingelheim, Bayer, Vifor Pharma, Astra Zeneca, Janssen-Cilag, Pfizer, GlaxoSmithKlein, Lilly. P.T.B. has received speaker honoraria and consultant fees from Sanofi-Genzyme, AstraZeneca, Alexion, Bayer, Travere, Pfizer, Novartis, Roche, Boehringer Ingelheim, and participated in advisory boards for Alexion, Sanofi-Genzyme, Novartis, Travere, and Bayer. A.G. has received speaker\/consultant honoraria and study fees from Alexion\/Astra Zeneca, Boehringer Ingelheim, Chiesi, Novartis, Sanofi, Roche and Vifor Pharma.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"202"}}